Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Understanding Leukaemia and Related Cancers

May 1, 2000
By Tariq I. Mughal, MB, MD, MRCP, FACP
Mary Cianfrocca, DO
Publication
Article
OncologyONCOLOGY Vol 14 No 5
Volume 14
Issue 5

Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a

 Patients who have newly diagnosed leukemia are often overwhelmed with the complexities of their disease and its required therapy. In their book, Understanding Leukaemia and Related Cancers, Drs. Mughal and Goldman offer patients a valuable guide to the diagnosis and treatment of leukemia. The authors note that the book is intended for a varied audience, but I believe that it will be most useful to patients and family members who seek a better understanding of the disease and its implications.

The book consists of eight chapters, the first three of which attempt to provide readers with the scientific background that will help them gain a better understanding of the disease process. The authors have done an excellent job of explaining complicated medical information in relatively easy-to-understand language, and the well-chosen illustrations will likely add to the reader’s comprehension.

The prevalence of leukemia, as well as the possible etiologies for its development, are discussed. Many patients fear that they may have done something to cause their cancer, and the authors go to some length to try to dispel these concerns. They also provide a valuable resource in Appendix 1—a list of many active support organizations in the United Kingdom, the United States, and Spain.

The remaining chapters describe the diagnosis and treatment of the various types of leukemia. Clear, simple language is used to explain the usual work-up that is performed on the leukemia patient, as well as the rationale behind various procedures.

The potential benefits and toxicities of chemotherapy and radiation are discussed, and a separate chapter on bone marrow transplantation is also included. The authors remember to include toxicities that occur with certain therapies, such as red urine with daunorubicin (Cerubidine), that are not dangerous but that, nonetheless, may be frightening to the unprepared patient.

The authors also address the importance of patient participation in clinical trials. They make the important point that 90% of children in the United Kingdom with acute lymphoblastic leukemia—a disease in which tremendous advances have been made—are entered into clinical trials.

Although the chapter on leukemia therapy is well written, it contains a few inaccuracies. For example, the section on the treatment of hairy-cell leukemia is outdated: Treatment with interferon is emphasized, and 2-chlorodeoxyadenosine (cladribine [Leustatin]) is mentioned only briefly. Also, the authors state that high-dose cytarabine is used only occasionally when, in fact, it has now become the standard consolidation therapy for many patients with acute myeloid leukemia.

The book’s final chapter ends on a hopeful note by discussing future therapeutic prospects. Targeted therapy, such as gene therapy, is described, as well as some of the controversies surrounding bone marrow transplantation.

Any book that informs patients is always a valuable resource. Despite its few shortcomings, Understanding Leukaemia and Related Cancers provides patients and their families with much of the information that they will need for proper decision-making throughout the course of their disease. It also manages to present this complicated information in a simple, nonthreatening manner. Patients will likely find this book to be most useful as a starting point for further discussion with their physicians.

Articles in this issue

Medicare Rethinking Its Policy on Self-Injectables
Home Counseling Program for Women With Lung Cancer to Be Studied
New Indication Sought for Bicalutamide
Approval of Antibody-Targeted Chemotherapy Recommended
NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer Planned
First Comparison of Anastrozole vs Tamoxifen
Prolonged Androgen Blockade May Boost Survival in Advanced Prostate Cancer
FDA Approves Irinotecan as First-Line Therapy for Colorectal Cancer
Understanding Leukaemia and Related Cancers
Bill Will Allow Doctors to Negotiate Jointly With HMOs
New Drug for Refractory Cutaneous T-Cell Lymphoma
New Clinical Trials Data Bank
Exisulind Shows Positive Results in the Prevention of Precancerous Colon Polyps
Commentary (Hewitt): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Commentary (Carr/Goudas): An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain
Recent Videos
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Leadership of a new cancer center as part of JFK University Medical Center discuss how they can support frontline clinicians.
Related Content
Advertisement

"SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed," according to Ajay Abad, MD, of Roswell Park Comprehensive Cancer Center.

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Russ Conroy
May 12th 2025
Article

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.


68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Arianna Cavalli;Susan Laura Jao;Skylar Harbour;Melissa Rony;Sheldon Feldman;Maureen McEvoy
May 10th 2025
Article
Related Content
Advertisement

"SurVaxM’s excellent safety profile and tolerability to date also help optimize quality of life for patients with this highly aggressive cancer, where additional treatment options are direly needed," according to Ajay Abad, MD, of Roswell Park Comprehensive Cancer Center.

Phase 2B Trial for Cancer Vaccine in Newly Diagnosed Glioblastoma Will Continue

Russ Conroy
May 12th 2025
Article

An independent data safety monitoring board determines that the phase 2b SURVIVE trial in newly diagnosed glioblastoma may continue without modification.


Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.


Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Advancing the Glioma Treatment Paradigm With Immunotherapy and Novel Strategies

Ariana Pelosci
May 12th 2025
Article

Nicholas Blondin, MD, provides an in-depth discussion on the evolving role of immunotherapy in the treatment of primary and metastatic brain tumors.


Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD
May 5th 2025
Podcast

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.


The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore
May 11th 2025
Article

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.


68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Arianna Cavalli;Susan Laura Jao;Skylar Harbour;Melissa Rony;Sheldon Feldman;Maureen McEvoy
May 10th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.